Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2011 1
2013 1
2014 2
2015 1
2016 2
2017 2
2018 4
2019 2
2020 2
2021 5
2022 12
2023 5
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for m assar,
Search for M Assmar, instead (2 results)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Cryptogenic stroke and underlying atrial fibrillation.
Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J; CRYSTAL AF Investigators. Sanna T, et al. N Engl J Med. 2014 Jun 26;370(26):2478-86. doi: 10.1056/NEJMoa1313600. N Engl J Med. 2014. PMID: 24963567 Free article. Clinical Trial.
Enhanced Contribution of Orai Channels to Contractility of Human Penile Smooth Muscle in Erectile Dysfunction.
Sevilleja-Ortiz A, El Assar M, García-Rojo E, Romero-Otero J, García-Gómez B, Fernández A, Medina-Polo J, La Fuente JM, Rodríguez-Mañas L, Angulo J. Sevilleja-Ortiz A, et al. J Sex Med. 2020 May;17(5):881-891. doi: 10.1016/j.jsxm.2020.02.020. Epub 2020 Mar 18. J Sex Med. 2020. PMID: 32199855
Orai inhibition could be a potential therapeutic strategy to reduce penile smooth muscle contraction in ED. Sevilleja-Ortiz A, El Assar M, Garcia-Rojo E, et al. Enhanced Contribution of Orai Channels to Contractility of Human Penile Smooth Muscle in Erectile Dysfunc …
Orai inhibition could be a potential therapeutic strategy to reduce penile smooth muscle contraction in ED. Sevilleja-Ortiz A, El Assar …
Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma.
Linder A, Westbom-Fremer S, Mateoiu C, Olsson Widjaja A, Österlund T, Veerla S, Ståhlberg A, Ulfenborg B, Hedenfalk I, Sundfeldt K. Linder A, et al. Hum Reprod. 2024 May 2;39(5):1141-1154. doi: 10.1093/humrep/deae043. Hum Reprod. 2024. PMID: 38459814 Free PMC article.
.), Roche in collaboration with the Swedish Society of Gynecological Oncology (S.W.-F.), Assar Gabrielsson Foundation (FB19-86, C.M.), and the Lena Wapplings Foundation (C.M.). ...
.), Roche in collaboration with the Swedish Society of Gynecological Oncology (S.W.-F.), Assar Gabrielsson Foundation (FB19-86, C. …
STIM/Orai Inhibition as a Strategy for Alleviating Diabetic Erectile Dysfunction Through Modulation of Rat and Human Penile Tissue Contractility and in vivo Potentiation of Erectile Responses.
Sevilleja-Ortiz A, El Assar M, García-Gómez B, La Fuente JM, Alonso-Isa M, Romero-Otero J, Martínez-Salamanca JI, Fernández A, Rodríguez-Mañas L, Angulo J. Sevilleja-Ortiz A, et al. J Sex Med. 2022 Dec;19(12):1733-1749. doi: 10.1016/j.jsxm.2022.08.200. Epub 2022 Oct 1. J Sex Med. 2022. PMID: 36195535
In vivo erectile responses to CNES. RESULTS: Inhibition of Orai channels with YM-58483 (20 M) significantly reduced adrenergic contractions in RCC but more effectively in DM. ...STIM/Orai inhibition could be a potential therapeutic strategy to overcome poor response to con …
In vivo erectile responses to CNES. RESULTS: Inhibition of Orai channels with YM-58483 (20 M) significantly reduced adrenergic contra …
Flecainide toxicity late after liver transplantation.
Elsaid O, Tecson KM, Khan H, Assar MD. Elsaid O, et al. Proc (Bayl Univ Med Cent). 2021 Jan 22;34(3):378-379. doi: 10.1080/08998280.2020.1871266. Proc (Bayl Univ Med Cent). 2021. PMID: 33953467 Free PMC article.
Inflammation suppresses DLG2 expression decreasing inflammasome formation.
Keane S, Herring M, Rolny P, Wettergren Y, Ejeskär K. Keane S, et al. J Cancer Res Clin Oncol. 2022 Sep;148(9):2295-2311. doi: 10.1007/s00432-022-04029-7. Epub 2022 May 2. J Cancer Res Clin Oncol. 2022. PMID: 35499706 Free PMC article. Clinical Trial.
DLG2 silencing in THP1 cells resulted in increased release of IL-6 into the microenvironment which once used to treat bystander COLO205 cells resulted in an increase in STAT3 phosphorylation and an increase proliferating cells and more cells in the G2/M phase. Restoration …
DLG2 silencing in THP1 cells resulted in increased release of IL-6 into the microenvironment which once used to treat bystander COLO205 cell …
Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer.
Larsson P, Pettersson D, Olsson M, Sarathchandra S, Abramsson A, Zetterberg H, Ittner E, Forssell-Aronsson E, Kovács A, Karlsson P, Helou K, Parris TZ. Larsson P, et al. Cell Death Discov. 2024 Jan 29;10(1):57. doi: 10.1038/s41420-024-01819-5. Cell Death Discov. 2024. PMID: 38286854 Free PMC article.
., bortezomib, delanzomib, and epoxomicin) were highly potent drugs in TNBC cells, of which bortezomib and delanzomib inhibited the chymotrypsin-like activity of the 20 S proteasome by 100% at 10 M. Moreover, several potent 2-drug combinations (e.g., bortezomib+nedaplatin …
., bortezomib, delanzomib, and epoxomicin) were highly potent drugs in TNBC cells, of which bortezomib and delanzomib inhibited the chymotry …
Impact of vaccination on COVID-19 outcome in multiple sclerosis.
Bsteh G, Gradl C, Heschl B, Hegen H, Di Pauli F, Assar H, Leutmezer F, Traxler G, Krajnc N, Zulehner G, Hiller MS, Rommer P, Wipfler P, Guger M, Enzinger C, Berger T; AUT-MuSC investigators. Bsteh G, et al. Eur J Neurol. 2022 Jul 5:10.1111/ene.15488. doi: 10.1111/ene.15488. Online ahead of print. Eur J Neurol. 2022. PMID: 35791496 Free PMC article.
41 results